In Brief: Masimo/Ivy Biomedical
This article was originally published in The Gray Sheet
Executive Summary
Masimo/Ivy Biomedical: Enter licensing agreement to allow integration of Masimo's SET signal extraction technology into Ivy's current and future pulse oximeter patient monitors, including its 405T portable multi-function monitor, 405D bedside monitor, and the soon-to-be-launched model 2000 stand-alone monitor. The SET is a pulse oximetry signal processing and sensor platform that allows measurement of weak physiological signals even in the presence of high levels of interfering signals or motion artifact, Masimo claims...
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.